Adapt has partnerd with biopharmaceutical firm Lightlake Therapeutics to develop treatments for opioid overdose. In December, Lightlake has agreed to license its opioid overdose reversal treatment to a
AR-12 is an orally-available small molecule. Data reported earlier shows that the mechanism of action of the molecule may include induction of host cell autophagy and inhibition of
The Enhanze platform is based on a proprietary recombinant human hyaluronidase enzyme (rHuPH20) that temporarily degrades hyaluronan, a chain of natural sugars in the body, to aid in
Both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have approved the brand name Galafold. Amicus Therapeutics chairman and CEO John Crowley said:
The VX-745 is an oral brain penetrant, which is highly selective and a potent inhibitor of the alpha isoform of the protein enzyme p38 mitogen activated protein kinase
Relistor is indicated for OIC treatment when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The approval of Relistor is
Fluzone Quadrivalent, a commercially available vaccine, is the active comparator in the VAX2012Q clinical trial. Around 450 healthy adults, aged 18-64, will be enrolled for the trial. They
The tablets are an alternative to Mucinex D (Guaifenesin/pseudoephedrine tablets), an expectorant indicated to relieve chest congestion and make coughs more productive. Perrigo will begin shipment of these
The research collaboration will advance the development of the French firm’s lead product candidate in AML, called UCART123. The deal will combine Weill Cornell’s expertise and resources in
Orphan drug status will provide the company with certain financial benefits such as tax credits for clinical trials, and waiver of prescription drug user fee for the marketing
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.